

Gherardo Mazziotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/219287/publications.pdf>

Version: 2024-02-01

268
papers

12,545
citations

25034

57
h-index

32842

100
g-index

285
all docs

285
docs citations

285
times ranked

10225
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucocorticoid-induced osteoporosis: pathophysiology and therapy. <i>Osteoporosis International</i> , 2007, 18, 1319-1328.	3.1	914
2	Growth Hormone, Insulin-Like Growth Factors, and the Skeleton. <i>Endocrine Reviews</i> , 2008, 29, 535-559.	20.1	715
3	Glucocorticoid-induced osteoporosis: an update. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 144-149.	7.1	311
4	Thyrotoxicosis in patients with COVID-19: the THYRCOV study. <i>European Journal of Endocrinology</i> , 2020, 183, 381-387.	3.7	262
5	Pseudohypoparathyroidism: Diagnosis and Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3020-3030.	3.6	250
6	Drug-induced Osteoporosis: Mechanisms and Clinical Implications. <i>American Journal of Medicine</i> , 2010, 123, 877-884.	1.5	234
7	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. <i>Pituitary</i> , 2017, 20, 489-498.	2.9	233
8	SARS-CoV-2-related atypical thyroiditis. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 739-741.	11.4	225
9	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. <i>Nature Reviews Endocrinology</i> , 2018, 14, 476-500.	9.6	224
10	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e937-e946.	3.6	207
11	Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1500-1508.	3.6	191
12	Growth Hormone, Insulin-Like Growth Factor-1, and the Kidney: Pathophysiological and Clinical Implications. <i>Endocrine Reviews</i> , 2014, 35, 234-281.	20.1	171
13	Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly. <i>PLoS ONE</i> , 2012, 7, e36411.	2.5	167
14	Diabetes in Cushing syndrome: basic and clinical aspects. <i>Trends in Endocrinology and Metabolism</i> , 2011, 22, 499-506.	7.1	164
15	Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross-Sectional Study in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1837-1844.	2.8	158
16	Prevalence of Vertebral Fractures in Men with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4649-4655.	3.6	144
17	Glucocorticoids and the regulation of growth hormone secretion. <i>Nature Reviews Endocrinology</i> , 2013, 9, 265-276.	9.6	144
18	Bone Turnover, Bone Mineral Density, and Fracture Risk in Acromegaly: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 384-394.	3.6	139

#	ARTICLE	IF	CITATIONS
19	New understanding and treatments for osteoporosis. <i>Endocrine</i> , 2012, 41, 58-69.	2.3	131
20	Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3402-3410.	3.6	131
21	Interferon- γ -Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3656-3661.	3.6	125
22	Cushing's Syndrome and Bone. <i>Pituitary</i> , 2004, 7, 249-252.	2.9	122
23	Advancing age and insulin resistance: role of plasma tumor necrosis factor- α . <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 275, E294-E299.	3.5	118
24	Long-term effects of lanreotide SR and octreotide LAR [®] on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. <i>Clinical Endocrinology</i> , 2002, 56, 65-71.	2.4	115
25	Recombinant Human TSH Modulates In Vivo C-Telopeptides of Type-1 Collagen and Bone Alkaline Phosphatase, but Not Osteoprotegerin Production in Postmenopausal Women Monitored for Differentiated Thyroid Carcinoma. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 480-486.	2.8	113
26	Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 520-528.	2.8	113
27	Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. <i>Diabetes Care</i> , 2020, 43, 3042-3049.	8.6	112
28	High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. <i>European Journal of Endocrinology</i> , 2009, 161, 331-338.	3.7	109
29	Pituitary Diseases and Bone. <i>Endocrine Reviews</i> , 2018, 39, 440-488.	20.1	107
30	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. <i>Journal of Neuro-Oncology</i> , 2016, 126, 519-525.	2.9	105
31	Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. <i>Obstetrics and Gynecology</i> , 2003, 101, 1177-1182.	2.4	102
32	Serum Thyrotropin Receptor Antibodies Concentrations in Patients with Graves' Disease Before, at the End of Methimazole Treatment, and After Drug Withdrawal: Evidence That the Activity of Thyrotropin Receptor Antibody and/or Thyroid Response Modify During the Observation Period. <i>Thyroid</i> , 2006, 16, 295-302.	4.5	102
33	Current and Emerging Aspects of Diabetes Mellitus in Acromegaly. <i>Trends in Endocrinology and Metabolism</i> , 2016, 27, 470-483.	7.1	102
34	Mutation of Somatostatin Receptor Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3809-3814.	3.6	99
35	Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. <i>Cancer</i> , 2002, 95, 2539-2545.	4.1	97
36	Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. <i>Bone</i> , 2010, 46, 747-751.	2.9	97

#	ARTICLE	IF	CITATIONS
37	Effect of Recombinant Human Growth Hormone (GH) Replacement on the Hypothalamic-Pituitary-Adrenal Axis in Adult GH-Deficient Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5397-5401.	3.6	91
38	Pseudohypoparathyroidism and Gs α -cAMP-linked disorders: current view and open issues. <i>Nature Reviews Endocrinology</i> , 2016, 12, 347-356.	9.6	91
39	Long-Term Outcome of Interferon- β -Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1925-1929.	3.6	90
40	Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 121-128.	3.6	88
41	Vertebral fractures in males with prolactinoma. <i>Endocrine</i> , 2011, 39, 288-293.	2.3	85
42	Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. <i>Pituitary</i> , 2010, 13, 60-67.	2.9	84
43	Thyrotropin-Secreting Pituitary Adenomas: Outcome of Pituitary Surgery and Irradiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2069-2076.	3.6	79
44	The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. <i>European Journal of Endocrinology</i> , 2002, 146, 743-749.	3.7	75
45	Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. <i>Endocrine-Related Cancer</i> , 2016, 23, 221-233.	3.1	75
46	The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. <i>Nature Immunology</i> , 2019, 20, 1012-1022.	14.5	75
47	Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. <i>Bone</i> , 2009, 45, 784-788.	2.9	73
48	Long-Term Outcome of Interferon- β -Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1925-1929.	3.6	72
49	High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. <i>Pituitary</i> , 2011, 14, 299-306.	2.9	70
50	Resistance to somatostatin analogs in acromegaly: An evolving concept?. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 86-93.	3.3	66
51	The Prevalence of GNAS Deficiency-Related Diseases in a Large Cohort of Patients Characterized by the EuroPHP Network. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3657-3668.	3.6	66
52	Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis. <i>European Journal of Endocrinology</i> , 2003, 148, 383-388.	3.7	64
53	Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon- β therapy for multiple sclerosis. <i>Journal of Endocrinological Investigation</i> , 1998, 21, 748-752.	3.3	63
54	Grey-scale analysis allows a quantitative evaluation of thyroid echogenicity in the patients with Hashimoto's thyroiditis. <i>Clinical Endocrinology</i> , 2003, 59, 223-229.	2.4	60

#	ARTICLE	IF	CITATIONS
55	Increased Cerebrospinal Fluid Levels of 3,3,5-Triiodothyronine in Patients with Alzheimer's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 198-202.	3.6	60
56	Bone and Joint Disorders in Acromegaly. <i>Neuroendocrinology</i> , 2016, 103, 86-95.	2.5	60
57	Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. <i>European Journal of Endocrinology</i> , 2010, 163, 15-20.	3.7	58
58	MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. <i>European Journal of Endocrinology</i> , 2017, 177, R231-R248.	3.7	58
59	Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3720-3725.	3.6	57
60	Reevaluating Thyrotropin Receptor-Induced Mouse Models of Graves' Disease and Ophthalmopathy. <i>Endocrinology</i> , 2005, 146, 835-844.	2.8	57
61	Growth hormone deficiency in the adult. <i>Pituitary</i> , 2006, 9, 305-311.	2.9	57
62	Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. <i>Endocrine</i> , 2016, 52, 103-110.	2.3	56
63	Recombinant Human GH Replacement Therapy in Children with Pseudohypoparathyroidism Type Ia: First Study on the Effect on Growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5011-5017.	3.6	55
64	Parity as a Thyroid Size-Determining Factor in Areas with Moderate Iodine Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4534-4537.	3.6	53
65	Effects of increased thyroxine dosage pre-conception on thyroid function during early pregnancy. <i>European Journal of Endocrinology</i> , 2004, 151, 695-700.	3.7	53
66	Influence of diabetes mellitus on vertebral fractures in men with acromegaly. <i>Endocrine</i> , 2011, 40, 102-108.	2.3	53
67	Genome-wide DNA methylation analysis of pseudohypoparathyroidism patients with GNAS imprinting defects. <i>Clinical Epigenetics</i> , 2016, 8, 10.	4.1	53
68	Pegvisomant in acromegaly: an update. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 577-589.	3.3	53
69	MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of vitamin D. <i>European Journal of Endocrinology</i> , 2018, 179, R239-R259.	3.7	53
70	High prevalence of radiological vertebral fractures in HIV-infected males. <i>Endocrine</i> , 2012, 41, 512-517.	2.3	52
71	High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. <i>Endocrine</i> , 2016, 54, 532-542.	2.3	52
72	Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. <i>Pituitary</i> , 2006, 9, 221-229.	2.9	51

#	ARTICLE	IF	CITATIONS
73	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2454-2464.	3.6	51
74	High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. <i>Bone</i> , 2004, 35, 785-791.	2.9	49
75	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. <i>Osteoporosis International</i> , 2014, 25, 441-446.	3.1	49
76	Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-12.	1.5	49
77	Evolution of thyroid autoimmunity during iodine prophylaxis—the Sri Lankan experience. <i>European Journal of Endocrinology</i> , 2003, 149, 103-110.	3.7	48
78	Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 624-630.	3.3	47
79	Screening of <i>PRKAR1A</i> and <i>PDE4D</i> in a Large Italian Series of Patients Clinically Diagnosed With Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1215-1224.	2.8	47
80	The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. <i>Pituitary</i> , 2008, 11, 13-20.	2.9	46
81	Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. <i>Pituitary</i> , 2009, 12, 196-199.	2.9	46
82	Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. <i>European Journal of Endocrinology</i> , 2011, 164, 341-347.	3.7	44
83	Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. <i>Pituitary</i> , 2007, 10, 227-232.	2.9	42
84	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. <i>Hormone Research in Paediatrics</i> , 2020, 93, 182-196.	1.8	42
85	MANAGEMENT OF ENDOCRINE DISEASE: Bone disorders associated with acromegaly: mechanisms and treatment. <i>European Journal of Endocrinology</i> , 2019, 181, R45-R56.	3.7	42
86	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E165-E172.	3.6	41
87	High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. <i>Bone</i> , 2016, 84, 88-92.	2.9	41
88	Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early-Onset Obesity. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1480-1488.	2.8	41
89	Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. <i>Pituitary</i> , 2008, 11, 55-61.	2.9	40
90	Parathyroid hormone pulsatility: physiological and clinical aspects. <i>Bone Research</i> , 2015, 3, 14049.	11.4	40

#	ARTICLE	IF	CITATIONS
91	High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-â€“Suppressive Therapy for Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 956-964.	3.6	39
92	Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. <i>European Journal of Endocrinology</i> , 2018, 179, 143-151.	3.7	39
93	Skeletal disorders associated with the growth hormone-â€“insulin-like growth factor 1 axis. <i>Nature Reviews Endocrinology</i> , 2022, 18, 353-365.	9.6	39
94	Acromegalic osteopathy. <i>Pituitary</i> , 2017, 20, 63-69.	2.9	38
95	Pituitary Diseases and Bone. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 171-180.	3.2	36
96	Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. <i>Endocrine</i> , 2018, 59, 90-101.	2.3	35
97	Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. <i>European Journal of Endocrinology</i> , 2014, 170, 893-899.	3.7	34
98	FLNA is implicated in pulmonary neuroendocrine tumors aggressiveness and progression. <i>Oncotarget</i> , 2017, 8, 77330-77340.	1.8	34
99	Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2001, 33, 247-253.	0.9	33
100	Innate and Acquired Immune System in Patients Developing Interferon-Î±-Related Autoimmune Thyroiditis: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4138-4144.	3.6	33
101	Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1619-1635.	4.1	33
102	The Modern Criteria for Medical Management of Acromegaly. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 138, 63-83.	1.7	33
103	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. <i>Bone</i> , 2017, 97, 147-152.	2.9	33
104	Octreotide for acromegaly treatment: a reappraisal. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2433-2447.	1.8	32
105	Diabetes in Cushing Disease. <i>Current Diabetes Reports</i> , 2017, 17, 32.	4.2	31
106	Insulin resistance and advancing age: What role for dehydroepiandrosterone sulfate?. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 1281-1286.	3.4	30
107	Thyroid Autoimmunity and Spontaneous Cervical Artery Dissection. <i>Stroke</i> , 2006, 37, 2375-2377.	2.0	30
108	Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1404-1412.	1.3	30

#	ARTICLE	IF	CITATIONS
109	Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes. <i>Age and Ageing</i> , 2008, 37, 222-225.	1.6	30
110	Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. <i>Pituitary</i> , 2018, 21, 302-308.	2.9	30
111	Long-term treatment with interferon- β therapy for multiple sclerosis and occurrence of Graves' disease. <i>Journal of Endocrinological Investigation</i> , 2000, 23, 321-324.	3.3	29
112	Bone safety of dual-release hydrocortisone in patients with hypopituitarism. <i>Endocrine</i> , 2018, 60, 528-531.	2.3	29
113	Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. <i>Endocrine</i> , 2018, 59, 449-453.	2.3	29
114	Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement. <i>Frontiers in Endocrinology</i> , 2015, 6, 187.	3.5	28
115	Adrenal Insufficiency at the Time of COVID-19: A Retrospective Study in Patients Referring to a Tertiary Center. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1354-e1361.	3.6	28
116	European guidance for the molecular diagnosis of pseudohypoparathyroidism not caused by point genetic variants at GNAS: an EQA study. <i>European Journal of Human Genetics</i> , 2015, 23, 438-444.	2.8	27
117	Current and future medical treatments for patients with acromegaly. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1631-1642.	1.8	27
118	Natural history of Rathke's cleft cysts: A retrospective analysis of a two centres experience. <i>Clinical Endocrinology</i> , 2018, 89, 178-186.	2.4	27
119	Lack of association between changes in plasma leptin concentration and in food intake during the menstrual cycle. <i>European Journal of Clinical Investigation</i> , 1999, 29, 490-495.	3.4	26
120	Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. <i>European Journal of Endocrinology</i> , 2022, 186, P1-P33.	3.7	26
121	GH receptor isoforms and skeletal fragility in acromegaly. <i>European Journal of Endocrinology</i> , 2014, 171, 237-245.	3.7	25
122	Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis. <i>Clinical Endocrinology</i> , 2003, 58, 207-212.	2.4	24
123	Recombinant Human Thyrotropin Reduces Serum Vascular Endothelial Growth Factor Levels in Patients Monitored for Thyroid Carcinoma Even in the Absence of Thyroid Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4818-4822.	3.6	24
124	Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. <i>European Journal of Endocrinology</i> , 2012, 167, 865-872.	3.7	24
125	Clinically Nonfunctioning Pituitary Incidentalomas: Characteristics and Natural History. <i>Neuroendocrinology</i> , 2020, 110, 595-603.	2.5	24
126	High leptin levels in women developing postpartum thyroiditis. <i>Clinical Endocrinology</i> , 2004, 60, 208-213.	2.4	23

#	ARTICLE	IF	CITATIONS
127	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	3.1	23
128	A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment. <i>International Journal of Cancer</i> , 2018, 142, 1842-1852.	5.1	22
129	Single-Molecule Microscopy Reveals Dynamic FLNA Interactions Governing SSTR2 Clustering and Internalization. <i>Endocrinology</i> , 2018, 159, 2953-2965.	2.8	22
130	Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies. <i>Journal of Clinical Oncology</i> , 2020, 38, 3363-3366.	1.6	22
131	Insulin and GH/IGF-I axis: endocrine pacer or endocrine disruptor?. <i>Acta Diabetologica</i> , 2015, 52, 433-443.	2.5	21
132	Skeletal Fragility in Endogenous Hypercortisolism. <i>Frontiers of Hormone Research</i> , 2016, 46, 66-73.	1.0	21
133	Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1679-1689.	1.8	21
134	Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2016, 13, 253-256.	1.0	21
135	Clinical utility gene card for: Pseudohypoparathyroidism. <i>European Journal of Human Genetics</i> , 2013, 21, 5-5.	2.8	20
136	Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. <i>Bone</i> , 2014, 67, 175-180.	2.9	20
137	Growth hormone deficiency in treated acromegaly. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 11-21.	7.1	20
138	Is Complex Sphenoidal Sinus Anatomy a Contraindication to a Transsphenoidal Approach for Resection of Sellar Lesions? Case Series and Review of the Literature. <i>World Neurosurgery</i> , 2017, 100, 173-179.	1.3	20
139	High bone marrow fat in patients with Cushing's syndrome and vertebral fractures. <i>Endocrine</i> , 2020, 67, 172-179.	2.3	20
140	Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves' disease: An unusual clinical coexistence. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 892-896.	3.3	19
141	HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway. <i>Journal of Molecular Medicine</i> , 2006, 84, 967-973.	3.9	19
142	Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma. <i>European Journal of Endocrinology</i> , 2015, 172, 363-369.	3.7	19
143	The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed. <i>Endocrine</i> , 2021, 71, 270-272.	2.3	19
144	Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. <i>European Journal of Endocrinology</i> , 2006, 154, 373-377.	3.7	18

#	ARTICLE	IF	CITATIONS
145	Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in) Tj ETQq1 1 0.784314 rgBT ₁₈ /Overl	3.6	18
146	Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2285-2293.	3.3	18
147	Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. <i>Osteoporosis International</i> , 2014, 25, 2263-2269.	3.1	17
148	cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion. <i>Experimental Cell Research</i> , 2015, 339, 241-251.	2.6	17
149	Expected and paradoxical effects of obesity on cancer treatment response. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 681-702.	5.7	17
150	Vertebral Fractures Associated with Spinal Sagittal Imbalance and Quality of Life in Acromegaly: A Radiographic Study with EOS 2D/3D Technology. <i>Neuroendocrinology</i> , 2021, 111, 775-785.	2.5	17
151	Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3720-3725.	3.6	17
152	Postintervention Serum TSH Levels May Be Useful to Differentiate Patients Who Should Undergo Levothyroxine Suppressive Therapy After Thyroid Surgery for Multinodular Goiter in a Region with Moderate Iodine Deficiency. <i>Thyroid</i> , 2000, 10, 1081-1085.	4.5	16
153	Iodized salt improves the effectiveness of l -thyroxine therapy after surgery for nontoxic goitre: a prospective and randomized study. <i>Clinical Endocrinology</i> , 2002, 57, 507-513.	2.4	16
154	Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy?. <i>Endocrine</i> , 2016, 52, 183-186.	2.3	16
155	High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma. <i>Journal of the Endocrine Society</i> , 2018, 2, 1089-1099.	0.2	16
156	Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. <i>Endocrine</i> , 2021, 73, 255-260.	2.3	16
157	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	3.7	16
158	Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 753-762.	3.3	16
159	The influence of parity on multinodular goiter prevalence in areas with moderate iodine deficiency. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 442-446.	3.3	15
160	Diagnostic features and outcome of surgical therapy of acromegalic patients: Experience of the last three decades. <i>Hormones</i> , 2014, 13, 95-103.	1.9	15
161	New medical therapies of acromegaly. <i>Growth Hormone and IGF Research</i> , 2016, 30-31, 58-63.	1.1	15
162	Focus on GH deficiency and thyroid function. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 71-78.	4.7	15

#	ARTICLE	IF	CITATIONS
163	Parathyroid hormone resistance syndromes – Inactivating PTH/PTHrP signaling disorders (iPPSDs). Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 941-954.	4.7	15
164	Prevalence and determinants of radiological vertebral fractures in patients with Klinefelter syndrome. Andrology, 2020, 8, 1699-1704.	3.5	15
165	Skeletal health in patients with differentiated thyroid carcinoma. Journal of Endocrinological Investigation, 2021, 44, 431-442.	3.3	15
166	Effects of Recombinant Follicle-Stimulating Hormone on Bone Turnover Markers in Infertile Women Undergoing <i>In Vitro</i> Fertilization Procedure. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 330-336.	3.6	14
167	Treatment of hypothyroidism: all that glitters is gold?. Endocrine, 2016, 52, 411-413.	2.3	14
168	Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2017, 31, 79-90.	4.7	14
169	Parity as a Thyroid Size-Determining Factor in Areas with Moderate Iodine Deficiency. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4534-4537.	3.6	14
170	Active acromegaly enhances spontaneous parathyroid hormone pulsatility. Metabolism: Clinical and Experimental, 2006, 55, 736-740.	3.4	13
171	Multiple hormone resistance and alterations of G-protein-coupled receptors signaling. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 141-154.	4.7	13
172	Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. Cancers, 2020, 12, 2143.	3.7	13
173	Inactivating PTH/PTHrP signaling disorders (iPPSDs): evaluation of the new classification in a multicenter large series of 544 molecularly characterized patients. European Journal of Endocrinology, 2021, 184, 311-320.	3.7	13
174	Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues. European Journal of Endocrinology, 2020, 183, L13-L15.	3.7	13
175	Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19 hospitalized patients. European Journal of Clinical Investigation, 2022, 52, e13753.	3.4	13
176	Biological activity of activating thyrotrophin receptor mutants: modulation by iodide. Journal of Molecular Endocrinology, 2005, 34, 209-220.	2.5	12
177	Biochemical Evaluation of Patients with Active Acromegaly and Type 2 Diabetes Mellitus: Efficacy and Safety of the Galanin Test. Neuroendocrinology, 2008, 88, 299-304.	2.5	12
178	Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect. Endocrine, 2014, 47, 354-356.	2.3	12
179	Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. Endocrine, 2017, 56, 146-157.	2.3	12
180	Impact of age on postsurgical outcomes of nonfunctioning pituitary adenomas. Endocrine, 2021, 72, 915-922.	2.3	12

#	ARTICLE	IF	CITATIONS
181	TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?. <i>Endocrine-Related Cancer</i> , 2020, 27, 325-336.	3.1	12
182	Spectral extinction measurements of spray combustion in a divided-chamber diesel engine system. <i>Proceedings of the Combustion Institute</i> , 1996, 26, 2533-2540.	0.3	11
183	Imbalance of the Osteoprotegerin/RANKL Ratio in Bone Marrow Microenvironment After Allogeneic Hemopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2006, 82, 1449-1456.	1.0	11
184	Treatment of glucocorticoid-induced osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2009, 1, 27-34.	2.7	11
185	Fibrocartilaginous mesenchymoma of bone: a single institution experience with molecular investigations and a review of the literature. <i>Histopathology</i> , 2017, 71, 134-142.	2.9	11
186	Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas. <i>Hormones and Cancer</i> , 2019, 10, 120-127.	4.9	11
187	Cardiovascular risk in aging and obesity: Is there a role for GH?. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 759-767.	3.3	10
188	Commentary. <i>Neurosurgery</i> , 2013, 73, E746-E748.	1.1	10
189	Growth hormone replacement therapy and fracture risk. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 307-308.	11.4	10
190	Recovery of Adrenal Function after Pituitary Surgery in Patients with Cushing Disease: Persistent Remission or Recurrence?. <i>Neuroendocrinology</i> , 2019, 108, 211-218.	2.5	10
191	A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2020, 509, 110803.	3.2	10
192	Hyperandrogenism by Liquid Chromatography Tandem Mass Spectrometry in PCOS: Focus on Testosterone and Androstenedione. <i>Journal of Clinical Medicine</i> , 2021, 10, 119.	2.4	10
193	GH deficiency in the adult and bone. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 18-23.	3.3	10
194	Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of WHO fracture risk assessment tool (FRAX) and bone mineral density in real-life clinical practice. <i>Journal of Bone Oncology</i> , 2022, 33, 100421.	2.4	10
195	Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?. <i>Journal of Internal Medicine</i> , 2002, 252, 377-378.	6.0	9
196	Pseudohypoparathyroidism type Ib in 2015. <i>Annales D'Endocrinologie</i> , 2015, 76, 101-104.	1.4	9
197	Long-Standing Isolated Autoimmune Hypophysitis Diagnosed with Endoscopic Transventricular Biopsy. <i>World Neurosurgery</i> , 2017, 105, 1036.e5-1036.e9.	1.3	9
198	Medullary thyroid carcinoma treated with percutaneous ultrasound-guided radiofrequency ablation. <i>Endocrine</i> , 2019, 65, 515-519.	2.3	9

#	ARTICLE	IF	CITATIONS
199	Abdominal Aortic Calcification as a Marker of Relationship Between Atherosclerosis and Skeletal Fragility. <i>Journal of Clinical Densitometry</i> , 2020, 23, 539-542.	1.2	9
200	Development of Gravesâ€™ hyperthyroidism during the early phase of pregnancy in a patient with pre-existing and long-standing Hashimotoâ€™s hypothyroidism. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 288-290.	3.3	8
201	Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-8.	1.5	8
202	Hypothyroidism associated with parathyroid disorders. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2017, 31, 161-173.	4.7	8
203	Secondary hyperparathyroidism and thoracic vertebral fractures in heart failure middle-aged patients: a 3-year prospective study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1561-1569.	3.3	8
204	Drug resistance in pituitary tumours: from cell membrane to intracellular signalling. <i>Nature Reviews Endocrinology</i> , 2021, 17, 560-571.	9.6	8
205	Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab. <i>Minerva Endocrinologica</i> , 2020, 45, 165-171.	1.8	8
206	TREATMENT WITH METFORMIN IS PROTECTIVE AGAINST LIMITATIONS IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER SUBJECTS WITH TYPE 2 DIABETES MELLITUS. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 562-564.	2.6	7
207	Elevated intraocular pressure in patients with acromegaly. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1133-1139.	1.9	7
208	Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic review. <i>Experimental Cell Research</i> , 2016, 346, 85-90.	2.6	7
209	Vitamin D and Glucocorticoid-Induced Osteoporosis. <i>Frontiers of Hormone Research</i> , 2018, , 149-160.	1.0	7
210	Pseudohypoparathyroidism, acrodysostosis, progressive osseous heteroplasia: different names for the same spectrum of diseases?. <i>Endocrine</i> , 2021, 72, 611-618.	2.3	7
211	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1660-e1672.	3.6	7
212	Glucocorticoid-induced osteoporosis and parathyroid hormone. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 16-21.	3.3	7
213	Direct effects of octreotide on osteoblast cell proliferation and function. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1045-1057.	3.3	7
214	Autoimmune Thyroiditis After Elimination of Iodine Deficiency in Sri Lanka. <i>Thyroid</i> , 2003, 13, 1187-1187.	4.5	6
215	Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma. <i>Pituitary</i> , 2010, 13, 289-292.	2.9	6
216	Update on vertebral fractures in pituitary diseases: from research to clinical practice. <i>Hormones</i> , 2021, 20, 423-437.	1.9	6

#	ARTICLE	IF	CITATIONS
217	Pseudohypoparathyroidism: Focus on Cerebral and Renal Calcifications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3005-e3020.	3.6	6
218	Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. <i>Frontiers in Endocrinology</i> , 2021, 12, 698963.	3.5	6
219	Prevention and treatment of glucocorticoid-induced osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 53-8.	3.3	6
220	Different expression of protein kinase A (PKA) regulatory subunits in normal and neoplastic thyroid tissues. <i>Histology and Histopathology</i> , 2015, 30, 473-8.	0.7	6
221	An Improved Polymerase Chain Reaction (PCR) Protocol for Unambiguous Detection of Growth Hormone Gene Deletions. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 1998, 11, 563-8.	0.9	5
222	Is chronic autoimmune thyroiditis a systemic disease?. <i>American Journal of Medicine</i> , 2003, 115, 412-413.	1.5	5
223	Letter to the Editor from Mazziotti et al: "Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-Based Study", <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3836-e3837.	3.6	5
224	Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice. <i>Endocrine</i> , 2020, 69, 204-211.	2.3	5
225	Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. <i>Molecular and Cellular Endocrinology</i> , 2021, 524, 111159.	3.2	5
226	Case Report: A Challenging Localization of a Pulmonary Ectopic ACTH-Secreting Tumor in a Patient With Severe Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 687539.	3.5	5
227	Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study. <i>European Journal of Endocrinology</i> , 2021, 185, 289-297.	3.7	5
228	Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 421.	2.7	5
229	Lack of <i>GNAS</i> Remethylation During Oogenesis May Be a Cause of Sporadic Pseudohypoparathyroidism Type 1b. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1610-e1619.	3.6	5
230	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges. <i>World Journal of Gastroenterology</i> , 2022, 28, 1430-1443.	3.3	5
231	Hypercalcaemia in pseudohypoparathyroidism type 1A and type 1B. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2019, 2019, .	0.5	4
232	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 1133-1143.	1.2	4
233	Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 1144-1155.	1.2	4
234	The "Parachute" Technique for the Endoscopic Repair of High-Flow Anterior Skull-Base CSF Leaks. <i>World Neurosurgery</i> , 2021, 151, e880-e887.	1.3	4

#	ARTICLE	IF	CITATIONS
235	Novel Pathogenetic Variants in PTHLH and TRPS1 Genes Causing Syndromic Brachydactyly. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 465-474.	2.8	4
236	Diagnosis and treatment of acromegaly and its complications: consensus guidelines. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 43-7.	3.3	4
237	Cortisol and the muscle-bone axis: response to comments by Molfino et al.. <i>Osteoporosis International</i> , 2015, 26, 1661-1662.	3.1	3
238	Unrecognized Pseudohypoparathyroidism Type 1A as a Cause of Hypocalcemia and Seizures in a 64-Year-Old Woman. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-5.	0.4	3
239	Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project. <i>Clinical Breast Cancer</i> , 2021, 21, e547-e560.	2.4	3
240	The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. <i>Molecular and Cellular Endocrinology</i> , 2021, 527, 111226.	3.2	3
241	Osteoporosis in Human Immunodeficiency Virus Patients – An Emerging Clinical Concern. <i>European Endocrinology</i> , 2010, 10, 79.	1.5	3
242	Diabetes insipidus and increased serum levels of leptin and lactate-dehydrogenase (LDH) in an adolescent boy with a primary intracranial germinoma. Case Report and an endocrinological reevaluation of literature. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 558-561.	3.3	2
243	Acromegalic osteopathy: An update. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 3, 1-6.	1.4	2
244	Prolactin: Regulation of Secretion and Action. , 2018, , 157-164.		2
245	FGF23 and Fetuin-A Interaction and Mesenchymal Osteogenic Transformation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 915.	4.1	2
246	Arterial Embolization and Second-Look in Spindle Cell Oncocytoma of the Pituitary Gland: Case Report and Review of Literature. <i>World Neurosurgery</i> , 2020, 142, 87-92.	1.3	2
247	The suprasellar volume of nonfunctioning pituitary adenomas: a useful tool for predicting visual field deficits. <i>Pituitary</i> , 2020, 23, 552-557.	2.9	2
248	A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature. <i>Endocrine</i> , 2020, 67, 466-472.	2.3	2
249	PTH resistance. <i>Molecular and Cellular Endocrinology</i> , 2021, 531, 111311.	3.2	2
250	Case Report: A Novel ARMC5 Germline Mutation in a Patient with Primary Bilateral Macronodular Adrenal Hyperplasia and Hypogammaglobulinemia. <i>Frontiers in Genetics</i> , 2022, 13, 834067.	2.3	2
251	The Importance of Networking in Pseudohypoparathyroidism: EuroPHP Network and Patient Support Associations. <i>Pediatric Endocrinology Reviews</i> , 2017, 15, 92-97.	1.2	2
252	Eight parathyroid glands incidentally discovered during a surgical intervention for secondary hyperparathyroidism: An unusual clinical finding. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 800-803.	3.3	1

#	ARTICLE	IF	CITATIONS
253	Molecular imaging in acromegaly. Nuclear Medicine Communications, 2014, 35, 897-899.	1.1	1
254	Brachydactyly and atrial septal defect: When the digits point to the heart. International Journal of Cardiology, 2014, 177, e90-e92.	1.7	1
255	Subclinical thyrotoxicosis and bone. Current Opinion in Endocrine and Metabolic Research, 2018, 3, 25-30.	1.4	1
256	Metformin and everolimus: A promising combination for neuroendocrine tumors treatment. Endocrine Abstracts, 0, .	0.0	1
257	Hypovitaminosis D and prevalence of vertebral fractures in women with GIO. Bone, 2009, 45, S140-S141.	2.9	0
258	Glucocorticoid-induced Osteoporosis. , 2010, , 415-421.		0
259	Neuroendocrinology of Bone Metabolism. Endocrinology, 2018, , 513-526.	0.1	0
260	Rathke's cleft cyst associated with pituitary granulomatosis with polyangiitis: An unusual combination of hypothalamus-pituitary region pathologies. Radiology Case Reports, 2018, 13, 233-236.	0.6	0
261	GH/IGF-I and Bone. , 2018, , 83-106.		0
262	Primary hyperparathyroidism in prostate cancer: guilty or not guilty?. Endocrine, 2018, 62, 271-273.	2.3	0
263	Case Report: Late-Onset Congenital Adrenal Hyperplasia and Acute Covid-19 Infection in a Pregnant Woman: Multidisciplinary Management. Frontiers in Endocrinology, 2020, 11, 602535.	3.5	0
264	Autoimmune Thyroid Disease. , 2004, , 461-490.		0
265	Neuroendocrinology of Bone Metabolism. Endocrinology, 2018, , 1-15.	0.1	0
266	The impact of body composition on vertebral fractures during aromatase inhibitors therapy: A cross-sectional study.. Journal of Clinical Oncology, 2018, 36, e12504-e12504.	1.6	0
267	Pseudohypoparathyroidism. VideoEndocrinology, 2022, 9, 2-3.	0.1	0
268	Somatostatin receptors regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations. Endocrine Oncology, 2022, , .	0.4	0